Clinical pharmacogenetics implementation consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing

Clinical Pharmacology and Therapeutics

Volumn 94, Issue 6, 2013, Pages 640-645

  Caudle, K E ^a   Thorn, C F ^b   Klein, T E ^b   Swen, J J ^c   McLeod, H L ^d   Diasio, R B ^e,f   Schwab, M ^g,h  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e MAYO CLINIC   (United States)

^f MAYO GRADUATE SCHOOL   (United States)

^g DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^h UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTINEOPLASTIC AGENT; CAPECITABINE; DIHYDROFLUOROURACIL; DIHYDROPYRIMIDINE DEHYDROGENASE; DRUG METABOLITE; FLUORO BETA ALANINE; FLUORO BETA UREIDOPROPIONATE; FLUOROPYRIMIDINE; FLUOROURACIL; MICRORNA; MULTIDRUG RESISTANCE PROTEIN 1; TEGAFUR; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG;

ALLELE; BONE MARROW SUPPRESSION; BREAST CANCER; CHEMOTHERAPY INDUCED EMESIS; COLORECTAL CANCER; DIARRHEA; DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY; DOSE RESPONSE; DRUG DEGRADATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TRANSFORMATION; DRUG URINE LEVEL; ENZYME ACTIVITY; EXON; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HAND FOOT SYNDROME; HAPLOTYPE; HETEROZYGOTE; HIGH RISK PATIENT; HOMOZYGOTE; HUMAN; INCIDENTAL FINDING; INTRON; METHYLATION; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PHARMACOGENETICS; PHENOTYPIC VARIATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; RISK BENEFIT ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SPLICING DEFECT; STOMATITIS; UNSPECIFIED SIDE EFFECT;

ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; FLUOROURACIL; GENOTYPE; HUMANS; INCIDENTAL FINDINGS; MALE; RISK ASSESSMENT; SEX FACTORS; TEGAFUR;

EID: 84888012165     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.172     Document Type: Review

References (40)

1. Diasio, R.B. & Harris, B.E. Clinical pharmacology of 5-fluorouracil. Clin. Pharmacokinet. 16, 215-237 (1989). (Pubitemid 19114713)
2. Relling, M.V. & Klein, T.E. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin. Pharmacol. Ther. 89, 464-467 (2011).
3. Thorn, C.F., Marsh, S., Carrillo, M.W., McLeod, H.L., Klein, T.E. & Altman, R.B. PharmGKB summary: fluoropyrimidine pathways. Pharmacogenet. Genomics 21, 237-242 (2011).
4. Fleming, R.A. et al. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res. 52, 2899-2902 (1992).
5. Johnson, M.R., Wang, K. & Diasio, R.B. Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. Clin. Cancer Res. 8, 768-774 (2002). (Pubitemid 34742106)
6. Wei, X. et al. Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics 51, 391-400 (1998). (Pubitemid 28413205)
7. Wei, X., McLeod, H.L., McMurrough, J., Gonzalez, F.J. & Fernandez-Salguero, P. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J. Clin. Invest. 98, 610-615 (1996). (Pubitemid 26349163)
8. Van Kuilenburg, A.B. et al. Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity. Eur. J. Cancer 33, 2258-2264 (1997). (Pubitemid 28123420)
9. Offer, S.M., Wegner, N.J., Fossum, C., Wang, K. & Diasio, R.B. Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using realtime cellular analysis and in vitro measurement of enzyme activity. Cancer Res. 73, 1958-1968 (2013).
10. Ofverholm, A., Arkblad, E., Skrtic, S., Albertsson, P., Shubbar, E. & Enerbäck, C. Two cases of 5-fluorouracil toxicity linked with gene variants in the DPYD gene. Clin. Biochem. 43, 331-334 (2010).
11. Schwab, M. et al.; German 5-FU Toxicity Study Group. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J. Clin. Oncol. 26, 2131-2138 (2008).
12. He, Y.F. et al. Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in Chinese cancer patients. J. Clin. Pharm. Ther. 33, 307-314 (2008).
13. Ben Fredj, R. et al. Mutational spectrum of dihydropyrimidine dehydrogenase gene (DPYD) in the Tunisian population. C. R. Biol. 330, 764-769 (2007). (Pubitemid 47457228)
14. Maekawa, K. et al. Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences. J. Hum. Genet. 52, 804-819 (2007). (Pubitemid 47512857)
15. Swen, J.J. et al. Pharmacogenetics: from bench to byte-an update of guidelines. Clin. Pharmacol. Ther. 89, 662-673 (2011).
16. van Kuilenburg, A.B. et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracilassociated toxicity: identification of new mutations in the DPD gene. Clin. Cancer Res. 6, 4705-4712 (2000). (Pubitemid 32110408)
17. Vreken, P., Van Kuilenburg, A.B., Meinsma, R. & van Gennip, A.H. Dihydropyrimidine dehydrogenase (DPD) deficiency: identification and expression of missense mutations C29R, R886H and R235W. Hum. Genet. 101, 333-338 (1997). (Pubitemid 28197529)
18. Morel, A. et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol. Cancer Ther. 5, 2895-2904 (2006). (Pubitemid 44849017)
19. Amstutz, U., Farese, S., Aebi, S. & Largiadèr, C.R. Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment. Pharmacogenomics 10, 931-944 (2009).
20. Offer, S.M., Lee, A.M., Mattison, L.K., Fossum, C., Wegner, N.J. & Diasio, R.B. A DPYD variant (Y186C) in individuals of african ancestry is associated with reduced DPD enzyme activity. Clin. Pharmacol. Ther. 94, 158-166 (2013).
21. Van Kuilenburg, A.B., Meinsma, R., Zoetekouw, L. & Van Gennip, A.H. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation. Int. J. Cancer 101, 253-258 (2002). (Pubitemid 34970893)
22. Amstutz, U., Froehlich, T.K. & Largiadèr, C.R. Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. Pharmacogenomics 12, 1321-1336 (2011).
23. Deenen, M.J. et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin. Cancer Res. 17, 3455-3468 (2011).
24. Noguchi, T. et al. Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells. Clin. Cancer Res. 10, 7100-7107 (2004). (Pubitemid 39383062)
25. Hirota, T. et al. Dihydropyrimidine dehydrogenase (DPD) expression is negatively regulated by certain microRNAs in human lung tissues. Lung Cancer 77, 16-23 (2012).
26. Van Kuilenburg, A.B., Meinsma, R., Zoetekouw, L. & Van Gennip, A.H. High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 12, 555-558 (2002). (Pubitemid 35177085)
27. Gross, E. et al. Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects. Hum. Mutat. 22, 498 (2003).
28. van Gennip, A.H., Abeling, N.G., Vreken, P. & van Kuilenburg, A.B. Inborn errors of pyrimidine degradation: clinical, biochemical and molecular aspects. J. Inherit. Metab. Dis. 20, 203-213 (1997). (Pubitemid 27273484)
29. Schmidt, C. et al. Comprehensive analysis of pyrimidine metabolism in 450 children with unspecific neurological symptoms using high-pressure liquid chromatography-electrospray ionization tandem mass spectrometry. J. Inherit. Metab. Dis. 28, 1109-1122 (2005). (Pubitemid 43168948)
30. van Staveren, M.C., Guchelaar, H.J., van Kuilenburg, A.B., Gelderblom, H. & Maring, J.G. Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency. Pharmacogenomics J. (2013); e-pub ahead of print 16 July 2013.
31. Yang, C.G. et al. DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity. Cancer Chemother. Pharmacol. 67, 49-56 (2011).
32. Capitain, O., Boisdron-Celle, M., Poirier, A.L., Abadie-Lacourtoisie, S., Morel, A. & Gamelin, E. The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer. Pharmacogenomics J. 8, 256-267 (2008). (Pubitemid 352038305)
33. Diasio, R.B., Beavers, T.L. & Carpenter, J.T. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J. Clin. Invest. 81, 47-51 (1988). (Pubitemid 18092231)
34. Maring, J.G. et al. Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. Br. J. Cancer 86, 1028-1033 (2002). (Pubitemid 34438069)
35. Boisdron-Celle, M. et al. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett. 249, 271-282 (2007). (Pubitemid 46452935)
36. Cellier, P. et al. Phase II study of preoperative radiation plus concurrent daily tegafur-uracil (UFT) with leucovorin for locally advanced rectal cancer. BMC Cancer 11, 98 (2011).
37. Jurecka, A. Inborn errors of purine and pyrimidine metabolism. J. Inherit. Metab. Dis. 32, 247-263 (2009).
38. Etienne, M.C. et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J. Clin. Oncol. 12, 2248-2253 (1994). (Pubitemid 24346691)
39. Milano, G., Etienne, M.C., Pierrefite, V., Barberi-Heyob, M., Deporte-Fety, R. & Renée, N. Dihydropyrimidine dehydrogenase deficiency and fluorouracilrelated toxicity. Br. J. Cancer 79, 627-630 (1999). (Pubitemid 29046246)
40. Gamelin, E. et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J. Clin. Oncol. 26, 2099-2105 (2008).